Background As new members of a drug class are developed, head-to-head trials are an
important strategy to guide personalised treatment decisions. We assessed two glucagon …

Objectives: To assess for the first time the safety and pharmacokinetics of an
antiprogrammed cell death-ligand 1 immune checkpoint inhibitor (BMS-936559; Bristol …

Purpose Sepsis-associated immunosuppression increases hospital-acquired infection and
viral reactivation risk. A key underlying mechanism is programmed cell death protein-1 (PD …

Aims/hypothesis The aim of this study was to compare the efficacy and safety of once-weekly
albiglutide with once-daily insulin glargine (A21Gly, B31Arg, B32Arg human insulin) in …

Introduction Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that
demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe …

Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs
used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular …

OBJECTIVE Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2,
improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability …

Objective To evaluate the effects of the T-cell costimulation blocker abatacept on anti-
citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) in early rheumatoid …

Objectives The primary objective was to identify well-tolerated doses of cimlanod in patients
with acute heart failure (AHF). Secondary objectives were to identify signals of efficacy …

This post hoc analysis of ACQUIRE (NCT00559585) explored the effect of baseline body
mass index (BMI) on the pharmacokinetics of and clinical response to subcutaneous (SC) or …